Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Alternative splicing and mutation status of CHEK2 in stage III breast cancer

V Staalesen, J Falck, S Geisler, J Bartkova, AL Borresen-Dale, J Lukas, JR Lillehaug, J Bartek, PE Lonning

. 2004 ; 23 (52) : 8535-8544.

Language English Country England, Great Britain

E-resources Online Full text

NLK Free Medical Journals from 1997 to 2004
ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Medline Complete (EBSCOhost) from 1997-01-09 to 2015-11-26
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago
Public Health Database (ProQuest) from 2000-01-01 to 1 year ago

The DNA damage checkpoint kinase, CHK2, promotes growth arrest or apoptosis through phosphorylating targets such as Cdc25A, Cdc25C, BRCA1, and p53. Both germline and somatic loss-of-function CHEK2 mutations occur in human tumours, the former linked to the Li-Fraumeni syndrome, and the latter found in diverse types of sporadic malignancies. Here we examined the status of CHK2 by genetic and immunohistochemical analyses in 53 breast carcinomas previously characterized for TP53 status. We identified two CHEK2 mutants, 470T>C (Ile157Thr), and a novel mutation, 1368insA leading to a premature stop codon in exon 13. The truncated protein encoded by CHEK2 carrying the 1368insA was stable yet mislocalized to the cytoplasm in tumour sections and when ectopically expressed in cultured cells. Unexpectedly, we found CHEK2 to be subject to extensive alternative splicing, with some 90 splice variants detected in our tumour series. While all cancers expressed normal-length CHEK2 mRNA together with the spliced transcripts, we demonstrate and/or predict some of these splice variants to lack CHK2 function and/or localize aberrantly. We conclude that cytoplasmic sequestration may represent a novel mechanism to disable CHK2, and propose to further explore the significance of the complex splicing patterns of this tumour suppressor gene in oncogenesis.

000      
00000naa a2200000 a 4500
001      
bmc14079627
003      
CZ-PrNML
005      
20141119213253.0
007      
ta
008      
141119s2004 enk f 000 0|eng||
009      
AR
035    __
$a (PubMed)15361853
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Staalesen, V. $u Department of Molecular Biology, University of Bergen, Bergen, Norway.
245    10
$a Alternative splicing and mutation status of CHEK2 in stage III breast cancer / $c V Staalesen, J Falck, S Geisler, J Bartkova, AL Borresen-Dale, J Lukas, JR Lillehaug, J Bartek, PE Lonning
520    9_
$a The DNA damage checkpoint kinase, CHK2, promotes growth arrest or apoptosis through phosphorylating targets such as Cdc25A, Cdc25C, BRCA1, and p53. Both germline and somatic loss-of-function CHEK2 mutations occur in human tumours, the former linked to the Li-Fraumeni syndrome, and the latter found in diverse types of sporadic malignancies. Here we examined the status of CHK2 by genetic and immunohistochemical analyses in 53 breast carcinomas previously characterized for TP53 status. We identified two CHEK2 mutants, 470T>C (Ile157Thr), and a novel mutation, 1368insA leading to a premature stop codon in exon 13. The truncated protein encoded by CHEK2 carrying the 1368insA was stable yet mislocalized to the cytoplasm in tumour sections and when ectopically expressed in cultured cells. Unexpectedly, we found CHEK2 to be subject to extensive alternative splicing, with some 90 splice variants detected in our tumour series. While all cancers expressed normal-length CHEK2 mRNA together with the spliced transcripts, we demonstrate and/or predict some of these splice variants to lack CHK2 function and/or localize aberrantly. We conclude that cytoplasmic sequestration may represent a novel mechanism to disable CHK2, and propose to further explore the significance of the complex splicing patterns of this tumour suppressor gene in oncogenesis.
590    __
$a bohemika - dle Pubmed
650    12
$a alternativní sestřih $7 D017398
650    02
$a sekvence nukleotidů $7 D001483
650    12
$a nádory prsu $x genetika $x metabolismus $7 D001943
650    02
$a checkpoint kinasa 2 $7 D064447
650    02
$a mutační analýza DNA $7 D004252
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    02
$a imunohistochemie $7 D007150
650    02
$a molekulární sekvence - údaje $7 D008969
650    12
$a mutace $7 D009154
650    02
$a polymerázová řetězová reakce $7 D016133
650    12
$a protein-serin-threoninkinasy $x genetika $x metabolismus $7 D017346
700    1_
$a Falck, J.
700    1_
$a Geisler, S.
700    1_
$a Bártková, Jiřina $7 xx0094304
700    1_
$a Borresen-Dale, A.L.
700    1_
$a Lukáš, Jiří $7 xx0094305
700    1_
$a Lillehaug, J.R.
700    1_
$a Bártek, Jiří, $d 1953- $7 xx0046271
700    1_
$a Lonning, P.E.
773    0_
$t Oncogene $x 0950-9232 $g Roč. 23, č. 52 (2004), s. 8535-8544 $p Oncogene $w MED00003600
773    0_
$p Oncogene $g 23(52):8535-44, 2004 Nov 4 $x 0950-9232
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20141119213332 $b ABA008
991    __
$a 20141119213332 $b ABA008
999    __
$a ok $b bmc $g 1047962 $s 878646
BAS    __
$a 3
BMC    __
$a 2004 $b 23 $c 52 $d 8535-8544 $x MED00003600 $i 0950-9232 $m Oncogene $n Oncogene
LZP    __
$a NLK 2014-1/lp

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...